UK Secures Zero Tariffs on Pharmaceuticals Amid Trump's Aggressive Trade Policy and Ongoing US Tariff Legal Battles

Welcome to United Kingdom Tariff News and Tracker, where we break down the latest on US trade policy, Donald Trump, and what it all means for the United Kingdom. The big story for UK listeners right now is that, amid sweeping US tariff hikes on allies and rivals alike, the UK has carved out at least one key safe lane. According to AOL News, British and American officials have agreed to keep tariffs on UK pharmaceutical exports to the US at zero, in exchange for the UK accepting higher drug prices in its own market. British officials say this “preferential tariff rate of 0%” for UK medicines into the US will apply across all UK pharmaceutical shipments, effectively locking in duty‑free access for one of Britain’s most valuable high‑tech export sectors. That zero‑tariff deal stands in stark contrast to the wider tariff landscape shaped by Donald Trump’s second administration. Trans.INFO reports that since September 2025 the US has imposed tariffs of around 15% on virtually all goods originating from the European Union, a move that has hit German industry particularly hard and disrupted EU–US supply chains. While the UK is no longer part of the EU, any broad, region‑based US tariff strategy raises the risk that UK goods could be pulled into new rounds of duties if relations sour or if Washington seeks “reciprocal” treatment across Europe. Trump has doubled down on tariffs as a central economic and political tool. The Economic Times notes that he has again floated the idea that tariffs could eventually replace federal income tax, arguing that rapidly rising tariff revenue could fund the government. Economists cited in that coverage call the idea “not possible” mathematically, pointing out that even at today’s elevated levels, tariffs still generate only a small fraction of federal revenue compared with income taxes and would shift the tax burden toward lower‑income households. At the same time, Euronews reports that Trump’s sweeping “Liberation Day” tariffs are facing a wave of legal challenges in the US Court of International Trade. More than 70 major companies, including Costco and Revlon, are suing to claw back duties and contest the use of emergency powers as a legal basis for broad, across‑the‑board tariffs. The US Supreme Court has already heard arguments on whether those powers were stretched too far, with a ruling expected by June 2026. A decision against the administration could force refunds, disrupt years of tariff collections, and potentially open a window for allies such as the UK to push for more stable, rules‑based tariff arrangements. For the United Kingdom, the key takeaways are clear: pharmaceuticals currently enjoy a rare zero‑tariff corridor into the US, but the broader American turn toward aggressive, politically driven tariffs keeps trade uncertainty high. UK exporters in autos, metals, food, and consumer goods will be watching both US courtrooms and the White House closely for the next move. Thanks for tuning in, and don’ This content was created in partnership and with the help of Artificial Intelligence AI.